Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

GALTGALT
27 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in GALECTIN THERAPEUTICS INC

CITADEL ADVISORS LLC holds 198,701 shares of GALT (GALECTIN THERAPEUTICS INC), worth $921,973 as of 2026-Q2. The position was decreased (-31.6% shares). GALT represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$921,973

Current Shares

198,701

Total Value Change

+$850,973

Total Shares Change

+177,974

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
198,701
-31.6%
$921,9730.0%$4.64
0
2026-Q1
New
290,360
-
$810,1040.0%$2.98
34
2025-Q4
Exited
0
-100.0%
$00.0%$4.08
0
2025-Q3
Decreased
71,306
-31.0%
$301,9810.0%$4.22
0
2025-Q2
New
103,297
-
$217,9570.0%$2.33
35
2024-Q3
Exited
0
-100.0%
$00.0%$2.71
0
2024-Q2
Decreased
823
-96.6%
$1,8600.0%$2.26
0
2024-Q1
Increased
24,521
+249.8%
$58,6050.0%$2.39
23
2023-Q4
New
7,010
-
$11,6370.0%$1.66
27
2023-Q3
Exited
0
-100.0%
$00.0%$1.92
0
2023-Q2
Decreased
428
-66.5%
$6160.0%$1.39
0
2023-Q1
Decreased
1,278
-98.5%
$2,6840.0%$2.17
0
2022-Q4
Increased
83,634
+361.1%
$94,5070.0%$1.13
24
2022-Q3
New
18,140
-
$29,0000.0%$1.65
30
2022-Q1
Exited
0
-100.0%
$00.0%$1.71
0
2021-Q4
Increased
43,382
+77.6%
$90,0000.0%$2.11
22
2021-Q3
New
24,432
-
$95,0000.0%$3.82
33
2021-Q1
Exited
0
-100.0%
$00.0%$2.03
0
2020-Q4
New
19,333
-
$43,0000.0%$2.30
31
2020-Q3
Exited
0
-100.0%
$00.0%$3.30
0
2020-Q2
Decreased
15,383
-70.2%
$47,0000.0%$3.04
0
2020-Q1
Increased
51,603
+365.3%
$101,0000.0%$1.98
24
2019-Q4
Decreased
11,091
-41.8%
$32,0000.0%$2.80
0
2019-Q3
New
19,046
-
$70,0000.0%$3.63
32
2019-Q2
Exited
0
-100.0%
$00.0%$4.15
0
2019-Q1
Decreased
20,411
-1.5%
$104,0000.0%$5.11
0
2018-Q4
New
20,727
-
$71,0000.0%$3.77
32

Other major holders of GALT: BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, OSAIC HOLDINGS, INC.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used